Current studies

Here at the DSRU, there is a variety of studies currently underway including:

Examples of studies currently underway at the DSRU

Drug name Brand name Background Study type
Asenapine Sycrest® Sycrest is a sublingual tablet
indicated for the treatment of moderate to severe manic episodes
associated with bipolar I disorder in adults. It was first marketed in
the UK in January 2012.
M-PEM
Asenapine Sycrest® Sycrest is a sublingual tablet
indicated for the treatment of moderate to severe manic episodes
associated with bipolar I disorder in adults. It was first marketed in
the UK in January 2012.
SCEM
(OBSERVA study)
Deferasirox Exjade® Exjade is indicated for the
treatment of chronic iron overload due to frequent blood transfusions
(≥7 ml/kg/month of packed red blood cells) in patients with beta
thalassaemia major aged 6 years and older. Exjade® was granted a
marketing authorisation by the European Commission on 28 August 2006.
PEM
Exenatide Bydureon® Bydureon is a prolonged-release
suspension for injection indicated for the treatment of type II
diabetes in combination with other diabetes medications in adults who
have not achieved adequate glycaemic control on maximally tolerated
doses of these oral therapies. It was first marketed in the UK in June
2011.
M-PEM
Rivaroxaban Xarelto® Xarelto is a tablet indicated
for the prevention of venous thromboembolism (VTE) in adult patients
undergoing elective hip or knee replacement surgery. It was first
marketed in the UK in September 2008.
M-PEM
Rivaroxaban Xarelto® Xarelto is a tablet indicated
for the prevention of venous
thromboembolism (VTE) in adult patients undergoing elective hip or knee
replacement surgery. It was first marketed in the UK in September 2008.
SCEM
(ROSE study)